12 Month Price Forecast For MLTX
Distance to MLTX Price Forecasts
MLTX Price Momentum
🤔 Considering MoonLake (MLTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 4:10 AM UTC
MLTX Analyst Ratings & Price Targets
Based on our analysis of 15 Wall Street analysts, MLTX has a consensus that is bullish. The median price target is $74.00, with forecasts ranging from $62.00 to $104.00. Currently, there are 14 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With MLTX currently trading at $45.06, the median price forecast suggests a 64.2% upside. The most optimistic forecast comes from Andreas Argyrides at Oppenheimer, projecting a 130.8% upside, while Serge Belanger at Needham provides the most conservative target, suggesting a 37.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MLTX Analyst Consensus
MLTX Price Target Range
Latest MLTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MLTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 17, 2025 | Goldman Sachs | Richard Law | Buy | Upgrade | $82.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Nov 5, 2024 | Wedbush | Yun Zhong | Outperform | Assumes | $73.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Sep 23, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Sep 12, 2024 | Needham | Serge Belanger | Buy | Reiterates | $62.00 |
| Sep 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Aug 26, 2024 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $0.00 |
| Aug 8, 2024 | Needham | Serge Belanger | Buy | Maintains | $62.00 |
| Jul 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Jun 25, 2024 | Oppenheimer | Andreas Argyrides | Outperform | Initiates | $104.00 |
| Jun 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| Jun 10, 2024 | Needham | Serge Belanger | Buy | Reiterates | $66.00 |
| May 17, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| May 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
| May 8, 2024 | Needham | Serge Belanger | Buy | Reiterates | $66.00 |
| Apr 23, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $100.00 |
Stocks Similar to MoonLake Immunotherapeutics
The following stocks are similar to MoonLake based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MoonLake Immunotherapeutics (MLTX) Financial Data
MoonLake Immunotherapeutics has a market capitalization of $2.97B with a P/E ratio of -61.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -16.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
MoonLake Immunotherapeutics (MLTX) Company Overview
About MoonLake Immunotherapeutics
Develops therapies for inflammatory diseases.
The company operates as a clinical-stage biopharmaceutical firm, focusing on the development of innovative therapies, particularly its lead candidate Sonelokimab, which targets various inflammatory conditions. Revenue generation will primarily stem from successful clinical trials, partnerships, and potential commercialization of their products.
Founded in 2021 and headquartered in Zug, Switzerland, MoonLake Immunotherapeutics is positioned in the growing biopharmaceutical market, which is driven by increasing demand for effective treatments for chronic inflammatory diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
50
CEO
Dr. Jorge Santos da Silva
Country
Switzerland
IPO Year
2020
Website
www.moonlaketx.comMoonLake Immunotherapeutics (MLTX) Latest News & Analysis
MoonLake Immunotherapeutics will release phase 3 VELA-1 and VELA-2 study results for sonelokimab in mid-2025, potentially leading to a BLA filing and increased shareholder value.
Results from the VELA studies could position sonelokimab as a leading IL-17 inhibitor, potentially driving market value and influencing stock performance for MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has initiated three new clinical trials for sonelokimab, targeting adolescent hidradenitis suppurativa, palmoplantar pustulosis, and axial spondyloarthritis. Data read-outs expected in 2025-2026.
The initiation of new trials for sonelokimab expands its potential market, increasing investor interest in MoonLake's growth and future revenue from multiple inflammatory disease indications.
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
4 months agoMoonLake Immunotherapeutics will host a Capital Markets Update on September 11, 2024, covering business updates, Phase 3 programs for sonelokimab, and pipeline developments.
MoonLake's Capital Markets Update reveals strategic insights on its clinical programs and pipeline, potentially impacting investor sentiment and stock performance based on upcoming trial results.
MoonLake Immunotherapeutics launched VELA-1 and VELA-2 studies for sonelokimab in Hidradenitis Suppurativa, with results due by end of 2026. The market may reach $1B by 2029. IZAR program for Psoriatic Arthritis to start Q4 2024.
MoonLake's new studies on sonelokimab target a growing $1 billion market, indicating potential revenue growth. Upcoming data releases in 2026 may impact stock valuation and investor interest.
MoonLake Immunotherapeutics has initiated the Phase 3 VELA program for sonelokimab, targeting moderate-to-severe hidradenitis suppurativa patients.
The initiation of Phase 3 trials for sonelokimab signals potential progress in treatment options, potentially impacting MoonLake's market position and future revenue streams.
MoonLake's sonelokimab shows promise in Phase 2 trials for psoriasis and hidradenitis suppurativa. The company has a strong financial position with a seven-year cash runway for Phase 3 trials.
MoonLake's sonelokimab shows promise in large markets and has a strong financial position, enhancing its potential for growth amid competition in the biotech sector.
Frequently Asked Questions About MLTX Stock
What is MoonLake Immunotherapeutics's (MLTX) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, MoonLake Immunotherapeutics (MLTX) has a median price target of $74.00. The highest price target is $104.00 and the lowest is $62.00.
Is MLTX stock a good investment in 2025?
According to current analyst ratings, MLTX has 14 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $45.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MLTX stock?
Wall Street analysts predict MLTX stock could reach $74.00 in the next 12 months. This represents a 64.2% increase from the current price of $45.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MoonLake Immunotherapeutics's business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on the development of innovative therapies, particularly its lead candidate Sonelokimab, which targets various inflammatory conditions. Revenue generation will primarily stem from successful clinical trials, partnerships, and potential commercialization of their products.
What is the highest forecasted price for MLTX MoonLake Immunotherapeutics?
The highest price target for MLTX is $104.00 from Andreas Argyrides at Oppenheimer, which represents a 130.8% increase from the current price of $45.06.
What is the lowest forecasted price for MLTX MoonLake Immunotherapeutics?
The lowest price target for MLTX is $62.00 from Serge Belanger at Needham, which represents a 37.6% increase from the current price of $45.06.
What is the overall MLTX consensus from analysts for MoonLake Immunotherapeutics?
The overall analyst consensus for MLTX is bullish. Out of 15 Wall Street analysts, 14 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $74.00.
How accurate are MLTX stock price projections?
Stock price projections, including those for MoonLake Immunotherapeutics, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
